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Abstract
Asthma has a high burden of morbidity if not controlled and may frequently complicate pregnancy, posing a risk for
pregnancy outcomes. Elevated plasma level of the inflammatory biomarker soluble urokinase plasminogen activator
receptor (suPAR) is related to a worse prognosis in many conditions such as infectious, autoimmune, or pregnancy-related
diseases; however the value of suPAR in asthma and asthmatic pregnancy is unknown. The present study aimed to
investigate the suPAR, CRP and IL-6 levels in asthma (asthmatic non-pregnant, ANP; N= 38; female N= 27) and asthmatic
pregnancy (AP; N = 15), compared to healthy non-pregnant controls (HNP; N= 29; female N= 19) and to healthy pregnant
women (HP; N= 58). The relationship between suPAR levels and asthma control was also evaluated. The diagnostic efficacy
of suPAR in asthma control was analyzed using ROC analysis. IL-6 and CRP levels were comparable in all study groups.
Circulating suPAR levels were lower in HP and AP than in HNP and ANP subjects, respectively (2.01 [1.81–2.38] and 2.39
[2.07–2.69] vs. 2.60 [1.82–3.49] and 2.84 [2.33–3.72] ng/mL, respectively, p = 0.0001). suPAR and airway resistance correlated
in ANP (r = 0.47, p = 0.004). ROC analysis of suPAR values in ANP patients with PEF above and below 80% yielded an AUC of
0.75 (95% CI: 0.57–0.92, p = 0.023) and with ACT total score above and below 20 an AUC of 0.80 (95% CI: 0.64–0.95,
p = 0.006). The cut-off value of suPAR to discriminate between controlled and not controlled AP and ANP was 4.04 ng/mL. In
conclusion, suPAR may help the objective assessment of asthma control, since it correlates with airway resistance and has
good sensitivity in the detection of impaired asthma control. Decrease in circulating suPAR levels detected both in healthy
and asthmatic pregnant women presumably represents pregnancy induced immune tolerance.
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Introduction
Asthma is a chronic inflammatory disease of the airways
characterized by variable and recurring symptoms, local inflam-
mation, reversible airflow obstruction, and bronchospasm (Global
Initiative for Asthma (GINA) guideline; [1]). Asthma is a prevalent
chronic disease which is not optimally controlled in up to 50% of
cases worldwide. It has a high burden of morbidity especially if not
controlled [1]; however blood biomarkers to identify patients at
risk are not available. Systemic inflammation in asthma causes an
acute phase response, as it was shown by increased level of C-
reactive protein (CRP) related to total immunglobulin (Ig)E levels
or respiratory symptoms of asthma [2,3]. Circulating interleukin
(IL)-6 is also a marker of inflammation [4] which is elevated in
asthmatic patients compared to healthy individuals and which
further increases after allergen challenge [5,6]. However, these
markers are not sufficiently sensitive to asthma control.
Asthma is one of the most common chronic diseases compli-
cating pregnancy [7]. It represents a risk for maternal and fetal
morbidities, including preterm delivery, gestational hypertension,
preeclampsia, low birth weight, and neonatal mortality [8,9]. On
the other hand, pregnancy may also influence the control of
asthma, leading to the deterioration of symptoms in one-third of
pregnant women [10]. Asthmatic pregnancy is characterized with
alteration in immune phenotype [11] and cytokine patterns [12].
Due to clinical and immunological interactions between asthma
and pregnancy women with asthma during pregnancy represent a
special challenge for asthma specialists. Optimal asthma control
during pregnancy is associated with lower risk of maternal and
neonatal complications [13]; therefore the identification of
pregnant women at risk of not controlled asthma and sufficient
symptom control is important in this patient group. However,
although some clinical factors including the severity of asthma
before pregnancy, disease worsening in previous pregnancies and
impaired asthma-specific quality of life in early pregnancy are
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predictive for the loss of asthma control during pregnancy
[9,10,14,15], to date systemic markers related to asthma control
determinants or lung function in asthmatic pregnancy are missing.
Over the recent years, soluble urokinase plasminogen activator
receptor (suPAR) has been emerged as a valuable indicator of the
activation state of the immune system. Urokinase-type plasmino-
gen activator receptor (uPAR) is expressed on various cell types,
including immune, smooth muscle and endothelial cells [16,17].
This membrane protein may be cleaved from the cell surface, thus
forming a free soluble receptor, suPAR [18]. suPAR is detectable
in low, but constant concentrations in plasma of healthy
individuals [18,19]. In contrast to C-reactive protein (CRP), the
suPAR levels are not affected by diurnal variation and fasting state
[20]. suPAR concentrations are resistant even to freezing and
thawing of plasma samples [21]. suPAR’s high stability in plasma
samples makes it an ideal candidate as a potential clinical
biomarker for inflammation. In many conditions such as in
infectious [22,23,24,25], autoimmune [26,27], and neoplastic
diseases [28], pregnancy [29] and pregnancy-related disorders
[30], higher than normal levels of suPAR were measured.
According to the data available, inflammatory response leads to
elevated plasma suPAR levels in many inflammatory diseases [31]
which is predictive to a worse prognosis [20,22,23,25,28,32].
Furthermore, suPAR appears to be a pre-clinical biomarker of
preeclampsia in late pregnancy [30].
In the present study we aimed to investigate the suPAR levels in
asthma and asthmatic pregnancy. The possible relationship
between suPAR and asthma control determinants was also
evaluated. In order to have a more complete view on systemic




Written informed consent was obtained from all subjects, and
our study was reviewed and approved by an independent ethical
committee of the institution (Institutional and Regional Research
Ethics Committee of Semmelweis Medical University). Laboratory
studies and interpretations were performed on coded samples
lacking personal and diagnostic identifiers. The study was adhered
to the tenets of the most recent revision of the Declaration of
Helsinki.
Study participants
The study had a cross-sectional design. 29 healthy non-pregnant
(HNP) controls (19 females and 10 males), 58 healthy pregnant
(HP) women, 38 asthmatic non-pregnant (ANP) patients (27
females and 11 males) and 15 asthmatic pregnant (AP) women
were enrolled. Asthmatic patients were assessed at their regular
visit at the outpatient clinic of the Department of Pulmonology,
Semmelweis University. They had persistent disease and asthma
had been diagnosed according to the current guidelines [1] at least
6 months prior to the study. Exclusion criteria were hypertension,
diabetes mellitus, autoimmune disease, angiopathy, renal disorder,
maternal or fetal infection, fetal congenital anomaly, multi-fetal
gestation, current smoking or more than 5 pack years of smoking
history, any other chronic disease (except for allergic rhinitis), and
acute infection within four weeks of measurement. Patients were
asked not to use their medication 12 hours before visits. Healthy
non-pregnant controls were volunteer blood donors and had a
negative history and negative status upon detailed physical and
routine laboratory examination. Healthy pregnant subjects were
recruited when attending their scheduled visit at the 1st
Department of Obstetrics and Gynaecology, Semmelweis Univer-
sity.
Laboratory procedures
Plasma was isolated from EDTA anticoagulated fasting blood
samples and stored at –80uC until measurement. Plasma suPAR
concentrations were measured with the suPARnostic Flex ELISA
assay (ViroGates A/S, Birkerød, Denmark). High-sensitivity (hs-
)CRP levels were measured using commercially available tests
(Roche Diagnostics GmbH, Mannheim, Germany). For the
determination of erythrocyte sedimentation rate (ESR), the
Westergren method was performed according to ICSH specifica-
tions (International Council for Standardization in Haematology,
1993) on undiluted EDTA anticoagulated blood samples using
glass pipettes (Greiner Bio-One, Kremsmuenster, Austria). During
sedimentation, the pipettes were mounted vertically on appropri-
ate supporting racks and kept at room temperature, which never
exceeded 25uC.
Lung function measurement and asthma control
evaluation
Lung function was measured by means of electronic spirometer
(PDD-301/s, Piston, Budapest, Hungary) according to the
American Thoracic Society (ATS) guidelines [33]. Three techni-
cally acceptable maneuvers were performed and the highest was
used. Forced expiratory volume in one second (FEV1), peak
expiratory flow rate (PEF), and airway resistance (Raw) were
measured. Asthma control was assessed using the Asthma Control
Test (ACT) suggested by the current [1] guideline.
Statistics
Data are expressed as median [interquartile range]. CRP values
below the level of detection (1 mg/L) were regarded as 1 mg/L.
IL-6 values below the level of detection (1.5 pg/mL) were
regarded as 1.5 pg/mL. Comparisons between the study groups
were made with Kruskal-Wallis tests. Correlation analyses were
performed using Spearman’s tests due to non-normal distribution
of data. Area Under Curve (AUC) values of Receiver Operating
Characteristics (ROC) curves were calculated using standard
methods and data are presented as AUC ROC (95% CI). p values
, 0.05 were considered significant. Statistics were calculated using
the SPSS software (version 20.0, SPSS, Inc. Chicago, IL, USA).
Results
Clinical characteristics
Clinical data and inflammatory parameters are summarized in
Table 1. The median age of participants was higher in the ANP
group compared to the HP and AP groups (39 [32–58] vs. 31 [28–
35] and 29.5 [26–32] years, respectively, p = 0.0001). Sampling
was performed in the second or third trimester of gestation in all
pregnant women, however, gestational age at blood collection was
lower in the AP than in the HP group (27.5 [24–33.5] vs. 36 [34–
38] weeks, p = 0.0002). Gestational age at delivery and fetal birth
weight were comparable in the pregnant groups. No difference
was detected either in parameters describing the severity or control
of asthma or in daily dose of inhaled corticosteroids between the
ANP and AP groups (Table 1).
Comparison of circulating marker levels among the four
groups
Treated asthma itself did not alter suPAR levels as ANP and
HNP groups had similar circulating suPAR levels (p.0.05; Figure
suPAR Levels in Asthma and Asthmatic Pregnancy
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1). Circulating suPAR values were lower in the HP and AP than in
the HNP and ANP subjects, respectively (2.01 [1.81–2.38] and
2.39 [2.07–2.69] vs. 2.60 [1.82–3.49] and 2.84 [2.33–3.72] ng/
mL, respectively, p = 0.0001). IL-6 levels were comparable in all
study groups. CRP values were comparable in the HNP, ANP and
HP groups and were higher in the AP group compared to the
HNP (7.00 [3.00–9.00] vs. 2.50 [1.00–3.90] mg/L, p = 0.005) but
not to the HP group (p.0.05) (Figure 1).
Relationship of inflammatory markers to asthma control
determinants and neonatal birth weight
PEF, Raw and ACT values were correlated with suPAR, IL-6
and CRP levels, respectively, in the ANP and AP groups.
Correlation analysis revealed a positive correlation between Raw
and suPAR levels (p = 0.004, r = 0.47) as well as Raw and IL-6
levels (p = 0.047, r = 0.35) in the ANP group (Figure 2), however
no such correlation was detected in the AP group. Similarly, no
correlation was observed between clinical parameters of asthma
and CRP in both asthmatic groups, and no correlation was
detected between the investigated inflammatory markers and
neonatal birth weight in the pregnant groups. Furthermore,
circulating suPAR levels were not influenced by the daily inhaled
corticosteroid dose of the patients.
As current asthma guideline suggests PEF . 80% and ACT
total score . 20 as the main determinants of well-controlled
asthma, ROC analyses of asthmatic patients’ data were performed
in subgroups of AP and ANP with PEF above and below 80% and
ACT total score above and below 20. ROC analyses in different
subgroups of ANP and AP patients according to PEF and ACT
scores proved to be statistically significant only in case of suPAR in
the ANP group, while p values were higher than 0.05 for IL-6 and
CRP and for all three biomarkers in the AP group. ROC analysis
of suPAR values in ANP patients with PEF above and below 80%
yielded an AUC of 0.75 (95% CI: 0.57–0.92, p = 0.023, Figure 3).









Female / male 19 / 10 – 27 / 11
Age (years) 36 [30–52] 31 [28–35] 39 [32–58]b 29.5 [26–32]c
Gestational age at sampling
(weeks)
– 36 [34–38] – 27.5 [24–33.5]b
Gestational age at delivery
(weeks)
– 39 [38–40] – 38 [38–39]
Fetal birth weight (grams) – 3255 [3090–3745] – 3320 [3000–4000]
FEV1 (% of predicted) – – 89.0 [83.5–98.0] 96.0 [82.0–108.0]
PEF (% of predicted) – – 90.5 [77.5–100.0] 89.0 [75.0–107.0]
Raw (% of predicted) – – 150 [92–179] 105 [84–127]
ACT total score – – 21.5 [17.5–24.0] 22.0 [18.5–25.0]
Daily dose of ICS (beclomethasone
equivalent, mg)
– – 1000 [800–1000] 1000 [375-1000]
CRP (mg/L) 2.50 [1.00–3.90] 3.85 [2.08–6.53] 3.00 [3.00–5.00] 7.00 [3.00–9.00]a
suPAR (ng/mL) 2.60 [1.82–3.49] 2.01 [1.81–2.38]a 2.84 [2.33–3.72]b 2.39 [2.07–2.69]c
IL-6 (pg/mL) 1.50 [1.50–1.70] 1.50 [1.50–2.18] 1.64 [1.50–3.36] 1.82 [1.50–3.43]
HNP – healthy non-pregnant; HP – healthy pregnant; ANP – asthmatic non-pregnant; AP – asthmatic pregnant; FEV1 – forced expiratory volume in 1 second; PEF – peak
expiratory flow rate; Raw – airway resistance; ACT – asthma control test; ICS – inhaled corticosteroid; CRP – C-reactive protein; suPAR – soluble urokinase plasminogen
activator receptor; IL-6 – interleukin 6; a p , 0.05 vs. HNP, b p , 0.05 vs. HP, c p , 0.05 vs. ANP.
doi:10.1371/journal.pone.0060697.t001
Figure 1. Circulating CRP (A), suPAR (B) and IL-6 (C) levels measured in healthy non-pregnant and pregnant, and asthmatic non-
pregnant and pregnant subjects. HNP – healthy non-pregnant; HP – healthy pregnant; ANP – asthmatic non-pregnant; AP – asthmatic pregnant;
CRP – C-reactive protein; suPAR – soluble urokinase plasminogen activator receptor; IL-6 – interleukin 6; ap,0.05 vs. HNP, bp,0.05 vs. HP and
cp,0.05 vs. ANP.
doi:10.1371/journal.pone.0060697.g001
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ROC analysis of suPAR values in ANP patients with ACT score
above and below 20 yielded an AUC of 0.80 (95% CI: 0.64–0.95,
p = 0.006, Figure 3). The cut-off value of suPAR to discriminate
between ANP patients with PEF above and below 80% was
4.04 ng/mL (sensitivity% (95% CI): 85.7 (67.3–96.0), specificity%
(95% CI): 40.0 (12.2–73.8), Table 2). The cut-off value of suPAR
to discriminate between ANP patients with an ACT score above
and below 20 was 4.04 ng/mL (sensitivity% (95% CI): 88.2 (63.6–
98.5), specificity% (95% CI): 46.2 (19.2–74.9); Table 2).
Discussion
This study is the first that investigates suPAR in asthma and
asthmatic pregnancy. According to our results, although treated
asthma generally is not associated with altered suPAR levels
(compared to healthy non-pregnant control data), in asthmatic
(non-pregnant) patients high suPAR indicated impaired lung
function. Furthermore, a cut-off value of suPAR was detected
which proved to be suitable to discriminate with high sensitivity
between ANP patients with controlled or uncontrolled disease. On
the other hand, a suPAR was consistently lower in pregnant
subjects regardless of asthma (compared to respective healthy and
asthmatic non-pregnant values).
Many studies have shown that increased levels of suPAR are
related to worse prognosis in diseases with active immune response
such as rheumathoid arthritis [27], infections [25], and patholog-
ical pregnancies [30]. Asthma is also associated with systemic
inflammation related to lung function and clinical symptoms [1].
Pregnancy on the other hand is characterized by immune
tolerance resulting in attenuation of immunological responses
[13]. Considerable amount of data support that impaired maternal
tolerance is responsible for adverse neonatal outcomes in
gestations complicated with uncontrolled asthma. In our earlier
study, fetal growth restriction was related to active, asthma-
associated maternal inflammatory responses in symptomatic
asthmatic pregnancy [34]. Therefore, it may be speculated that
fetal well-being and optimal growth might depend on sufficient
regulation of immune responses during pregnancy and also that
Figure 2. Positive correlation of airway resistance (Raw) to circulating suPAR (A) and to circulating IL-6 (B) levels in asthmatic non-
pregnant patients. suPAR – soluble urokinase plasminogen activator receptor; IL-6 – interleukin 6.
doi:10.1371/journal.pone.0060697.g002
Table 2. Cut-off values of the inflammatory markers.
Sensitivity Specificity Cut-off value
ANP according to PEF, CRP 74.1 (53.7–88.9) % 30.0 (6.7–65.3) % . 4.50 mg/L
ANP according to PEF, suPAR 85.7 (67.3–96.0) % 40.0 (12.2–73.8) % . 4.04 ng/mL*
ANP according to PEF, IL-6 78.3 (56.3–92.5) % 40.0 (12.2–73.8) % . 2.90 pg/mL
ANP according to ACT, CRP 31.3 (11.0–58.7) % 76.9 (46.2–95.0) % . 4.50 mg/L
ANP according to ACT, suPAR 88.2 (63.6–98.5) % 46.2 (19.2–74.9) % . 4.04 ng/mL*
ANP according to ACT, IL-6 81.8 (59.7–94.8) % 45.5 (16.8–76.6) % . 2.90 pg/mL
AP according to PEF, CRP 60.0 (26.2–87.8) % 66.7 (9.4–99.2) % . 7.50 mg/L
AP according to PEF, suPAR 80.0 (44.4–97.5) % 60.0 (14.7–94.7) % . 2.57 ng/mL
AP according to PEF, IL-6 70.0 (34.8–93.3) % 50.0 (6.8–93.2) % . 2.48 pg/mL
AP according to ACT, CRP 62.5 (24.5–91.5) % 60.0 (14.7–94.7) % . 7.50 mg/L
AP according to ACT, suPAR 77.8 (40.0–97.2) % 50.0 (11.8–88.2) % . 2.57 ng/mL
AP according to ACT, IL-6 75.0 (34.9–96.8) % 50.0 (11.8–88.2) % . 2.48 pg/mL
Table shows the cut-off values of the inflammatory markers to discriminate between patients with PEF above and below 80% and ACT total score above and below 20,
respectively in the asthmatic non-pregnant (ANP) and asthmatic pregnant (AP) groups.
PEF – peak expiratory flow rate; CRP – C-reactive protein; suPAR – soluble urokinase plasminogen activator receptor; IL-6 – interleukin 6; ACT – asthma control test; * p
, 0.05.
doi:10.1371/journal.pone.0060697.t002
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decrease in suPAR level in pregnant groups in this study
(regardless of the presence of mostly controlled asthma) was the
sign of the immune tolerance caused by pregnancy.
Although Yokoyama and coworkers have reported that patients
with stable allergic and non-allergic asthma exhibited an increase
in circulating IL-6 [5], our results show comparable IL-6 levels in
all study groups. This apparent contradiction between our data
and previous results may be based on different definition of stable
asthma and lack of inhaled steroid treatment in the latter but not
in our study. Furthermore, one should note that the most marked
alteration of IL-6 levels was detected during asthmatic attack in
the studies of Yokoyama.
It is known from recent studies that CRP is elevated in asthma
and that high CRP is associated with respiratory impairment or
bronchial hyperresponsiveness [2,35,36]. Other studies showed
that CRP levels are only elevated in steroid naı¨ve asthmatic
patients, but not in those taking inhaled corticosteroids (ICS)
regularly [37]. In our experiments CRP was comparable among
the four study groups, except for a limited increase measured in
asthmatic pregnant compared to healthy non-pregnant but not
healthy pregnant group. This is in agreement with previous
findings and can be explained by the fact that most of the
asthmatic patients examined in this study were taking ICS. On the
other hand, the small elevation of CRP in asthmatic pregnant
women could be explained with non-adherence to steroid
treatment as pregnant asthmatics are known to be less compliant
to take the prescribed ICS regularly [10]. Thus, a limitation of our
study is the lack of known steroid-naı¨ve patients. A further
confounding factor may be the age difference of patients as
asthmatic non-pregnant patients were older than AP women;
however it must be noted that suPAR levels are not expected to be
influenced by this slight difference of age [38].
Little is known about inflammatory mechanisms inducing
increased production of mucus, causing mucosal edema or
hypertrophy of the smooth muscles in the bronchi, but all these
changes increase airway resistance and severity of asthma [39,40].
Whether suPAR and IL-6 play a role in regulation of the above
processes needs further investigation. To test their potential
contribution, PEF, Raw and ACT values were correlated with
suPAR and IL-6 levels in asthmatic groups and a positive
correlation was found both between suPAR and Raw and between
IL-6 and Raw, suggesting a possible role of these inflammatory
molecules in the development of asthmatic airway narrowing and
increased airway resistance.
The potential value of CRP, suPAR and IL-6 in the
determination of asthma control was analyzed using ROC
analysis. Since the current asthma guideline suggests PEF.80%
predicted and ACT total score.20 as the main determinants of
well-controlled asthma, ROC analyses of asthmatic patients’ data
were performed in subgroups of patients with PEF above and
below 80% and ACT total score above and below 20. ROC
analysis of suPAR values based on PEF yielded a cut-off point of
4.04 ng/ml, with an AUC of 0.75. A slightly better performance of
suPAR was measured when patients were discriminated on the
Figure 3. ROC analyses of suPAR values in asthmatic non-pregnant patients (A, B) and asthmatic pregnant patients (C, D) with good
and impaired asthma control. ANP – asthmatic non-pregnant, AP – asthmatic pregnant; PEF – peak expiratory flow rate, ACT – Asthma Control
Test total score.
doi:10.1371/journal.pone.0060697.g003
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basis of ACT, where AUC was 0.8 at a cut-off value of 4.04 ng/
ml. This could be explained by the fact that ACT measures
diversified symptoms (daytime symptom frequency, rescue thera-
py, sleep frequency and activity limitations; [41]) and, unlike PEF,
did not provide information exclusively about the ability to breath.
Of note, the diagnostic performance of suPAR was much lower in
asthmatic pregnancy than in non-pregnant asthmatics. Further-
more, the cut-off values have a satisfactory sensitivity coupled with
limited specificity, indicating that the sole usage of suPAR as a
marker of asthma control might overestimate uncontrolled
patients.
In summary, suPAR is a promising biomarker of asthma control
in asthmatic non-pregnant patients, since it correlates with airway
resistance and has good sensitivity in the detection of impaired
asthma control. However, future studies are needed to demon-
strate whether the suggested diagnostic value of suPAR would
translate into clinical practice. A pregnancy specific decrease can
be detected in circulating suPAR levels both in healthy and
asthmatic pregnant women. Theoretically, this may be the result
of immune tolerance in pregnancy and the attenuation of systemic
inflammatory responses.
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